Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNAVAC 001: CN54ENV DNA Vaccine for HIV
NCT03663998Phase 1Completed
- Sponsor
- Imperial College London
- Start
- Aug 2015
- Primary completion
- May 2017
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
Phase 1, open-label trial of CN54ENV in human immunodeficiency virus infection (HIV) (9 arms), sponsored by Imperial College London. Primary endpoints: Reactogenicity at 12 Months, Vaccine-related unsolicited adverse events at 14 Months and 1 more. Started Aug 2015; status: completed.
02
Drugs
CN54ENV
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03663998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03663998.